مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

221
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

166
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

INTRAVITREAL INJECTION OF BEVACIZUMAB: REVIEW OF OUR PREVIOUS EXPERIENCE (SHORT COUMUNICATION)

Pages

  1093-1098

Abstract

 Several ocular and systemic complications have been reported after the BEVACIZUMAB INTRAVITREAL INJECTION. This study aims at reporting the main indications for the BEVACIZUMAB INTRAVITREAL INJECTION in our center, the INTRAVITREAL INJECTION method in this study, and the incidence of the post-injection complication, such as ENDOPHTHALMITIS. This study is a retrospective review of the consecutive intravitreal BEVACIZUMAB (AvastinÒ) injections for 359 patients between 2011 and 2013 at a single institute (Poostchi Clinic of Ophthalmology). Before the injection, adrop containing 5 mL Ciprofloxacin and 5 mL Betadine 10% was applied 3 times at the intervals of 10 min. The eye lashes, upper and lower eyelids, and caruncle were swabbed with Betadine 10% but the lid speculum, drape, and conjunctival washing were not conducted. The patients were followed up 8 weeks after the injection for the evaluation of any complications. In this study, 1376 INTRAVITREAL INJECTION of BEVACIZUMAB in 479 eyes of 359 patients were enrolled. Among them, 141patients (39.3%) were men and 218 (60.7%) were women. The mean age (± SD) of the patients was 61.48 (± 11.21) years. On average, each patient received 3.83 (the range 1-13) injections. The most common indications for the BEVACIZUMAB INTRAVITREAL INJECTION were diabetic retinopathy, choroidal neovascularization, and central retinal vein occlusion. None of the patients developed ENDOPHTHALMITIS, retinal detachment, or other adverse effects. This study showed that the above-mentioned method of the intravitreal BEVACIZUMAB injection is easy and safe. The future studies involving more participants are required for the evaluation of rare complications.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    AFARID, MEHRDAD, SADEGHI SARVESTANI, ALI, RAHAT, FEISAL, & AZIMI, ALI. (2018). INTRAVITREAL INJECTION OF BEVACIZUMAB: REVIEW OF OUR PREVIOUS EXPERIENCE (SHORT COUMUNICATION). IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), 17(3), 1093-1098. SID. https://sid.ir/paper/288782/en

    Vancouver: Copy

    AFARID MEHRDAD, SADEGHI SARVESTANI ALI, RAHAT FEISAL, AZIMI ALI. INTRAVITREAL INJECTION OF BEVACIZUMAB: REVIEW OF OUR PREVIOUS EXPERIENCE (SHORT COUMUNICATION). IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR)[Internet]. 2018;17(3):1093-1098. Available from: https://sid.ir/paper/288782/en

    IEEE: Copy

    MEHRDAD AFARID, ALI SADEGHI SARVESTANI, FEISAL RAHAT, and ALI AZIMI, “INTRAVITREAL INJECTION OF BEVACIZUMAB: REVIEW OF OUR PREVIOUS EXPERIENCE (SHORT COUMUNICATION),” IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), vol. 17, no. 3, pp. 1093–1098, 2018, [Online]. Available: https://sid.ir/paper/288782/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button